Showing 981-990 of 1057 results for "".
- FDA Okays Initiation of Phase 1/2 Trial of Gene Therapy for Krabbe Diseasehttps://practicalneurology.com/news/fda-okays-initiation-of-phase-12-trial-of-gene-therapy-for-krabbe-disease/2469466/The Food and Drug Administration (FDA) gave clearance for the first-in-human adeno-associated viral (AAV) gene therapy (FBX-101; Forge Biologics, Columbus, OH) for potential treatment of Krabbe disease. In preclinical trials in animal models, this gene therapy corrected the central and peripheral
- FDA Clears IND Application of Gene Therapy for Tay-Sachs and Sandhoff Diseaseshttps://practicalneurology.com/news/fda-clears-ind-application-of-gene-therapy-for-tay-sachs-and-sandhoff-diseases/2469420/The Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a registrational study of adeno-associated viral (AAV) vector gene therapy (AXO-AAV-GM2; Axovant Gene Therapies, New York, NY) to treat individuals with Tay-Sachs disease and Sandhoff dis
- New No-Cost Course for Professionals in Stroke Centers with High-Volume of COVID-19https://practicalneurology.com/news/new-no-cost-course-for-professionals-in-stroke-centers-with-high-volume-of-covid-19/2469417/The American Heart Association is offering an education course for healthcare professionals on stroke care with considerations for additional protocols and care practices that come with the COVID-19 pandemic. This course is made possible by support from the Leona B. and Harry M. H
- Music and Memory Program Decreased Need for Antipsychotic Treatment in Dementiahttps://practicalneurology.com/news/music-and-memory-program-decreased-need-for-antipsychotic-treatment-in-dementia/2469359/Researchers at the Betty Irene Moore School of Nursing at UC Davis found that personalized music programming is associated with a reduction in the amount of antipsychotic medication taken by nursing home residents. Individuals who had personalized playlists also had fewer distressed behaviors. Re
- Alzheimer Disease Risk May Be Measurable in Adolescence and Early Adulthoodhttps://practicalneurology.com/news/alzheimer-disease-risk-may-be-measurable-in-adolescence-and-early-adulthood/2469340/According to data from multiple studies reported at the Alzheimer’s Association International Conference (AAIC) 2020, risk factors for dementia from Alzheimer disease (AD) may be apparent as early as second or third decade of life. In the study of healthy aging in Afri
- Blood Tests for Alzheimer Disease Advancehttps://practicalneurology.com/news/blood-tests-for-alzheimer-disease-advance/2469338/At the Alzheimer’s Association International Conference (AAIC) 2020, results from several studies reported potential blood test measures for diagnosis and disease monitoring of Alzheimer disease (AD). Most relied on assaying for the presence of various isoforms of phosphorylated tau, p-tau2
- FDA Accepts Supplemental New Drug Application for Pimavanserin for Dementia-Related Psychosis Symptomshttps://practicalneurology.com/news/fda-accepts-supplemental-new-drug-application-for-pimavanserin-for-dementia-related-psychosis-symptoms/2469329/The Food and Drug Administration (FDA) has accepted for filing its supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The sNDA is
- New Indication for Pimavanserin—Dementia Related Psychosis—Submitted to the FDAhttps://practicalneurology.com/news/new-indication-for-pimavanserin-dementia-related-psychosis-submitted-to-the-fda/2469301/A supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaseuticals, San Diego, CA) was submitted to the Food and Drug Administration (FDA) for a new indication. Evidence now shows pimavanserin is effective for the treatment of hallucinations and delusions associated wit
- Phase 3 Trial of MSC-NTF Stem Cells for ALS Receives Continued Fundinghttps://practicalneurology.com/news/phase-3-trial-of-msc-ntf-stem-cells-for-als-receives-continued-funding/2469289/The ongoing phase 3 clinical trial of autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, Paramus, NJ) treatment has received funding through a grant. The grant was awarded by the ALS Association and
- Cardiovascular Disease Risk Tripled for American Indians and Alaska Nativeshttps://practicalneurology.com/news/cardiovascular-disease-risk-tripled-for-american-indians-and-alaska-natives/2469279/According to a scientific statement published in the American Heart Association journal Circulation, type 2 diabetes affects American Indians and Alaska natives at approximately 3 times the rate of white Americans and is closely linked to disproportionately high rates of cardiovascular disease.</